0A9G fundamentals
An in-depth look to MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS operating, investing, and financing activities
0A9G free cash flow for Q4 24 is -9.33 M USD. For 2024, 0A9G free cash flow was -32.85 M USD and operating cash flow was -32.85 M USD.
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '24
Q2 '24
Q3 '24
Q4 '24
TTM